Page |1
Perez, Jaycee F.
BSN 2B
DRUG STUDY
NAME OF DRUG
Generic Name:
>Ceftadizime
Brand Name:
>Ceptaz
Dosage:
>300 ml
Route:
Through IV
Frequency
>q8
Form:
>Solution
CLASSIFICATION
OF ACTION
Anti-infectives
>Third generation
Cephalosporin that
inhibit cell-wall
synthesis
Promoting osmotic
instability: usually
bactericidal
INDICATIONS
>treatment for end-stage renal
disease (ESRD). Peritonitis for
peritoneal catheterization
ADVERSE
REACTION
CNS: Seizures,
headache,
dizziness,
parethesia
CV: Phlebitis,
thrombophlebitis
GI: nausea,
vomiting,
diarrhea,
abdominal
cramps
Hematologic:
agranulocytosis,
leukopenia,
eosinophilia
SKIN:
maculopapular
and arthenayous
rashes
OTHER:
Anaphylaxis
CONTRAINDICATIONS
>Contraindicated in
patients
hypersensitive to
drugs or other
cephalosporins
>Use cautiously in
patients
hypersensitive to
penicillin because of
possibility of crosssensitivity with other
beta-lactam
antibiotics
NURSING
RESPONSIBILITY
MONITORING PARAMETERS
>Obtain specimen
fior culture and
sensitivity tests
before giving first
dose. Therapy
may begin while
awaiting results
>May increase alkaline
phosphatase ALT, AST,
bilirubin and LDH levels. May
decrease hemoglobin level.
>For IM use inject
deep into a large
muscle, such as
the gluteus
maximus or the
side of the thigh
>May increase eosinophil
count. May decrease
granulocyte and WBC counts
ALT=5 – 28 u/L
BUN=8.2 – 20 mg/dL
Creatinine= 0.4 – 0.7 mg/dL
AST= 15 – 30 u/L
Bilirubin=0 – 3.4 umol/L
Hgb=12 – 16 g/Dl
WBC= 4,500 – 11,000 cubic
mm
Eosinophil= 0 – 4%
Platelet= 150,000 –
4500.000 cubic mm
LDH= 60 – 160 mg/dL